Pericardial effusion due to hypothyroidism

Article written and reviewed by Dr Luca Moretti

A pericardial effusion due to hypothyroidism is an accumulation of fluid associated with thyroid hormone deficiency, generally through altered capillary permeability and lymphatic reabsorption. It may accompany known inadequately controlled thyroid disease or be one of the findings leading to diagnosis. The collection is often slowly progressive and may become large without pericarditic pain or a marked inflammatory response.

The term myxedema heart describes a group of cardiovascular manifestations of severe hypothyroidism, including effusion, a relatively low heart rate and electrocardiographic abnormalities. It does not mean tamponade and does not necessarily imply myxedema coma. The clinical problem is to establish whether hormone deficiency truly explains the fluid and whether compromise requires decompression before replacement therapy can take effect.

In stable patients, treatment of the endocrine cause may lead to regression without drainage. This possibility should not become a rule of waiting in unstable forms: cardiac tamponade remains an emergency even when the etiology is correctable with levothyroxine.

Thyroid deficiency, etiologic settings and causal probability

Primary hypothyroidism may result from autoimmune thyroiditis, thyroidectomy, radioiodine, iodine deficiency or excess in predisposed settings, and drugs that alter thyroid function. A history of definitive treatment for hyperthyroidism is particularly useful when replacement therapy has been stopped or taken irregularly. The effusion depends not only on the TSH value measured at presentation, but also on the duration and depth of the deficiency and on concomitant cardiovascular conditions.

Central hypothyroidism requires attention because TSH may be low, normal or inappropriately only slightly elevated relative to reduced free thyroxine. An apparently reassuring TSH therefore does not exclude deficiency in the presence of pituitary or hypothalamic disease. Assessment includes the other hormonal axes, especially the adrenal axis, because starting thyroid replacement in unrecognized adrenal insufficiency may precipitate deterioration. Diagnosis should not rely on the screening test used for primary forms alone.

Biochemical severity increases the plausibility of causation when accompanied by coherent clinical signs and absence of better explanations. A modest isolated TSH elevation with normal free thyroxine should not automatically be considered responsible for a large effusion. Subclinical hypothyroidism is common in some populations and may be coincidental. Etiologic judgment therefore requires proportionality among the degree of deficiency, phenotype and course, avoiding stopping the investigation at the first laboratory abnormality.

Observed frequency varies widely among series, eras and severity of hypothyroidism. Percentages from advanced myxedema series do not describe the risk in people diagnosed early and effectively replaced. Systematic use of echocardiography also identifies small collections that do not have the same meaning as symptomatic forms. It is inappropriate to transfer a heterogeneous epidemiologic range to an individual patient without considering the population from which it was derived.

Ineffective therapy may result from incomplete adherence, intake with food or interfering substances, malabsorption and changing requirements. Iron and calcium, for example, can reduce levothyroxine absorption if taken without adequate separation. The history should reconstruct actual administration, formulation and recent changes, without assuming that a documented prescription corresponds to adequate exposure. The problem may be organizational or pharmacologic and may not simply require an indiscriminate dose increase.

Concomitant causes remain possible even with marked deficiency: malignancy, renal failure, infection, heart failure and autoimmune disease may contribute to the collection. Autoimmune thyroiditis alone does not prove systemic autoimmune pericarditis. Regression during hormonal correction strengthens attribution, whereas growth, fever or an unexpected response should reopen the work-up. Causal diagnosis remains a synthesis of clinical and longitudinal data, not the mere coincidence of two common findings.

Pathogenesis and hemodynamic adaptation

Altered exchange promotes passage of proteins, especially albumin, into the interstitial space and serous cavities, while lymphatic drainage may be less efficient. The net balance produces accumulation without necessarily requiring an acute inflammatory pericardial process. This distinction explains the frequent absence of pain and the limited usefulness of anti-inflammatory drugs when there are no independent indications. Fluid is a manifestation of systemic exchange dysfunction, not merely of a local lesion of the sac.

Slow formation allows the pericardium to adapt progressively and accommodate relatively large amounts with an initially limited rise in pressure. The reserve is not unlimited, however: once exhausted, further increases or a fall in filling pressures may cause compression. An apparently compensated patient may therefore worsen during dehydration, infection or other intercurrent conditions. The endocrine cause suggests an often slow natural history but does not guarantee hemodynamic stability.

Reduced thyroid hormone action on the cardiovascular system decreases chronotropy and contractility and alters diastolic relaxation. Increased peripheral resistance may be associated with elevated diastolic pressure, while cardiac output and exercise tolerance decline. These effects may coexist with the effusion without being caused by it. Dyspnea should therefore not be attributed entirely to the fluid, and its regression after replacement may reflect recovery of several physiological components.

A relatively low heart rate is a useful clue but not a diagnostic rule. In severe hypothyroidism, the tachycardic response to circulatory compromise may be attenuated; drugs and conduction disorders may contribute. Absence of tachycardia does not exclude tamponade. Conversely, a high heart rate may result from infection, anemia or shock and does not automatically argue against hypothyroidism. Meaning emerges from comparison with perfusion, blood pressure, temperature and clinical course.

The echoclinical discordance described in large myxedematous collections includes atrial inversion, right-sided collapse or flow variations without equivalent clinical compromise. The term pseudotamponade is used to emphasize this discrepancy but should not become an automatic explanation for compressive signs. Expert and serial assessment is necessary because the risk is twofold: unnecessarily draining a stable patient or underestimating true progression toward low output.

Decompensated myxedema adds hypoventilation, hypothermia, neurologic abnormalities, hyponatremia and possible multiorgan dysfunction. In this setting, hypotension and reduced perfusion may have several simultaneous mechanisms. Echocardiography helps define the contribution of fluid, while endocrine and intensive-care assessment address systemic deficiency and precipitating factors. The presence of effusion does not by itself explain all abnormalities, just as recognition of myxedema does not eliminate the need to look for correctable compression.

Clinical manifestations and recognition of risk

Incidental presentation is possible during investigation of fatigue, dyspnea or other diseases. An enlarged cardiac silhouette on radiography may raise suspicion but does not distinguish effusion from cardiac enlargement. Echocardiography clarifies the finding. The patient may have gradually reduced activity, making onset less apparent: comparing independence, walking and stair tolerance with the preceding months helps identify limitation that a generic question about symptoms may miss.

Signs of hypothyroidism include cold intolerance, dry skin, constipation, voice changes, slowing, weight gain and delayed reflex relaxation, with considerable variability. No single sign is necessary or sufficient. In older adults or patients with multiple diseases, the picture may be subtle and attributed to deconditioning. A history of thyroid surgery, radioiodine or failure to take replacement therapy may be more informative than an apparently nonspecific clinical appearance.

Progressive dyspnea may result from the collection, diastolic dysfunction, respiratory muscle weakness or associated disease. Pleuritic chest pain, fever and friction rub are not required and, when prominent, suggest an inflammatory component or an alternative cause requiring investigation. A large effusion may produce a sense of fullness and compressive symptoms, but anatomic size must be related to actual circulatory impact before deciding on a procedure.

The circulatory examination assesses blood pressure, peripheral perfusion, mental status, urine output and venous pressure, in addition to heart rate. Pulsus paradoxus and jugular venous distension may support compromise but are not always present. Muffled heart sounds are poorly specific. Preserved blood pressure does not exclude a compensated phase, while hypotension in severe hypothyroidism may also result from infection or adrenal insufficiency. Judgment requires concordance of data and reassessment if the picture evolves.

Signs of endocrine decompensation include altered consciousness, hypothermia, hypoventilation and severe systemic slowing. Coma is not required to recognize a critical myxedematous state. Infection, cold exposure, sedatives or interruption of therapy may precipitate it. Stabilization requires hospital care, often intensive, and treatment of the trigger. These patients should not be managed as a simple outpatient TSH follow-up associated with an echocardiographic finding.

Assessment of alternatives includes constitutional symptoms, infectious contacts, known malignancy, renal failure, trauma and medications. Unexplained weight loss, lymphadenopathy, persistent fever or a rapidly enlarging collection are concerning even with documented hypothyroidism. A plausible endocrine diagnosis should not reduce attention to a second cause. The goal is to identify the dominant mechanism without missing concomitant conditions that would change treatment, urgency or prognosis of the pericardial disease.

Endocrine diagnosis, imaging and additional investigations

The thyroid profile should include TSH and free thyroxine to define the severity and probable level of deficiency. In overt primary hypothyroidism, TSH is elevated and free thyroxine is reduced; in central forms the relationship differs. Acute illness, medications and analytical interferences may complicate interpretation. A result inconsistent with the picture requires reasoned verification without delaying treatment of a critical condition when the clinical evidence is sufficiently convincing.

Thyroid antibodies may point toward an autoimmune cause but do not measure the responsibility of the deficiency for the collection or guide levothyroxine dosing. Thyroid ultrasound is selected for structural indications and is not required solely because an effusion exists. If pituitary disease is suspected, assessment of other axes and appropriate imaging are needed. Endocrine etiologic investigation serves to make replacement effective and durable, not to replace assessment of cardiac risk.

Echocardiography describes size, distribution, chamber collapse, respiratory flows and ventricular function. When compressive signs are present with apparent stability, judgment should be clinical and serial, avoiding both a procedure based on a single finding and reassurance based on the thyroid cause. Regional collections, right-sided dysfunction and volume changes may modify expression. Comparison with previous studies clarifies the rate of change and provides a reference for documenting response.

The ECG may show low voltage, repolarization abnormalities, prolonged QT and a low heart rate, but none of these changes alone identifies the cause. Electrical alternans may occur with large collections. Complete blood count, electrolytes, creatinine, C-reactive protein and further tests guided by clinical suspicion help identify complications and competing diagnoses. Troponin is interpreted in context, especially when pain, possible ischemia or unexplained ventricular dysfunction is present.

CT or cardiac MRI is reserved for specific questions such as a mass, complex localization, inflammation or myocardial disease. They are not mandatory steps before treating a plausible thyroid deficiency in a stable patient. If fluid is drained, cytology and microbiology depend on the alternatives considered. Biochemistry does not provide a signature specific to hypothyroidism: protein content or color does not replace clinical attribution and proportionate exclusion of other causes.

The longitudinal diagnosis is strengthened by biochemical improvement and regression of the collection during effective replacement. Adherence and absorption must be verified before therapeutic failure is declared. Slow reduction does not necessarily imply an incorrect cause, but growth or deterioration requires immediate review. The pathway must also define the appropriate level of care: major symptoms, severe systemic deficiency, hemodynamic uncertainty or inability to ensure reliable follow-up may require hospital management.

Hormone replacement and management of severe myxedema

Levothyroxine is the reference treatment for deficiency and, in cases attributable to the endocrine cause, promotes fluid reabsorption. Rapid emptying of the sac is not necessary in every stable patient. Initial dose depends on age, weight, duration of deficiency and cardiovascular disease. In a younger adult without heart disease, replacement close to the full requirement may be appropriate, whereas a gradual strategy reduces the risk of ischemia or arrhythmia in vulnerable patients.

Initial doses should not be uniform. NICE recommendations suggest about 1.6 micrograms/kg/day in adults under 65 years without a cardiovascular history and a lower starting dose in older adults or those with heart disease. In known coronary artery disease, traditional specialist guidance often uses 12.5-25 micrograms/day with cautious titration. These schemes describe different settings, not interchangeable protocols; selection must also consider clinical severity and the need for correction in a monitored environment.

The method of administration affects the result. Consistency in relation to meals, separation from iron and calcium, and review of interfering medications can correct an apparently high requirement. If the response remains inadequate, adherence, malabsorption and formulation should be assessed before repeatedly increasing the dose. TSH normalization takes time and does not justify daily adjustments. In central hypothyroidism, monitoring is based mainly on free thyroxine and the clinical picture, not on trying to normalize TSH.

Adrenal reserve should be considered when pituitary disease, unexplained hypotension, hypoglycemia or critical myxedema is suspected. If adrenal insufficiency is a risk, glucocorticoid coverage precedes or accompanies thyroid replacement according to the clinical pathway. This is not anti-inflammatory treatment of the effusion. Samples for diagnostic testing are obtained when possible without delaying treatment of an unstable patient.

Myxedema coma requires intensive care, respiratory and circulatory support, cautious correction of metabolic abnormalities and treatment of the precipitating factor. ATA guidelines recommend intravenous levothyroxine with an individualized loading dose, generally 200-400 micrograms in adults, reduced in older patients or those with heart disease, followed by adjusted maintenance. Liothyronine, when used, is a selected specialist option because of cardiac risk. Systemic severity changes the route and pace of therapy but does not replace treatment of concomitant tamponade.

Anti-inflammatory drugs are not indicated solely to accelerate disappearance of a non-inflammatory collection. Aspirin, NSAIDs, colchicine and corticosteroids require a separate pericardial or systemic indication. Diuretics likewise do not correct the thyroid mechanism and may worsen filling if overused in a compressive setting. Drug management should therefore treat the deficiency and actual comorbidities, avoiding addition of standard pericarditis therapies to a phenotype with different pathophysiology.

Indications for drainage and initial monitoring

Clinically significant tamponade requires decompression even if levothyroxine has already been started. Hormonal response is not fast enough to correct urgent compromise. Hypotension, hypoperfusion, respiratory deterioration and concordant echocardiographic findings require timely treatment assessment. The procedure is selected according to distribution and accessibility, with imaging guidance and appropriate expertise, without waiting for normalization of thyroid tests before treating the circulation.

A stable patient with a large collection may instead be managed conservatively when the cause is plausible, alternatives have been assessed and monitoring is reliable. The presence of some echocardiographic signs of compression requires greater attention, not an automatic rule. Perfusion, symptoms, venous pressure and trend should be documented. If stability is uncertain, a period of inpatient observation allows the clinical trajectory to be verified and rapid access to decompression arranged if needed.

Diagnostic drainage may be appropriate when there is substantial suspicion of malignancy or infection, an atypical collection or an unexplained lack of response. It is not required in every case to prove thyroid origin. A procedure should have a question and expected benefit, balanced against risk and the probability that the sample will change therapy. The decision is particularly important when hypothyroidism is modest relative to the size of the effusion or inconsistent systemic signs coexist.

Early reassessment includes symptoms, heart rate, blood pressure, renal function and echocardiography according to severity. Biochemical thyroid monitoring follows timing compatible with pharmacokinetics and the clinical picture, generally on the order of weeks in stable forms. The endocrine schedule does not replace the cardiology schedule: a significant collection may require reassessment before TSH reaches its new equilibrium. Conversely, repeating echocardiography without a question does not replace verification of replacement efficacy.

The expected response may require weeks or months for complete regression. Symptomatic improvement with a still-visible collection does not necessarily mean failure, provided there is stability and a favorable trend. If fluid increases, administration, absorption and competing causes should be checked rather than merely increasing the dose. Repeating already-negative investigations should be guided by new clues to keep the pathway targeted and reduce procedures without concrete benefit.

Post-drainage surveillance checks residual fluid, ventricular function and possible reaccumulation. Thyroid replacement must continue because evacuation does not correct the systemic defect. Post-procedural deterioration requires investigation for injury, bleeding, decompression dysfunction or another disease rather than automatic attribution to myxedema. Even in an etiologically clear case, follow-up remains necessary until endocrine and cardiac stabilization, with a plan linking the different specialists.

Prognosis, complications and prevention of recurrence

Pericardial prognosis is generally favorable when the deficiency is recognized and corrected and no other causes are present. Slow formation of the collection explains sometimes surprising tolerance but should not be confused with absence of risk. Tamponade and compression of adjacent structures are possible in major forms. Recovery should be measured through function and symptoms as well as echocardiography because hormone deficiency simultaneously affects several cardiovascular components.

Systemic complications of severe hypothyroidism include metabolic disturbances, hypoventilation, neurologic abnormalities and vulnerability to intercurrent illness. The prognosis of decompensated myxedema is very different from that of a stable incidentally discovered effusion. Coronary artery disease, renal failure and other comorbidities also modify risk and speed of recovery. It is therefore inappropriate to assign every thyroid-related effusion a single favorable outlook without describing severity of deficiency and general condition.

Toxicity from excess replacement should be prevented, especially in patients at arrhythmic or ischemic risk. Overly aggressive correction in a vulnerable setting may increase myocardial demand and promote angina or arrhythmias. The desire to make the fluid disappear rapidly does not justify overdosing. Adjustments should respond to appropriate endocrine targets and the clinical picture, not isolated echocardiographic changes that may evolve more slowly.

Recurrence may indicate renewed inadequacy of therapy, malabsorption, interactions or a different cause. Review of prescriptions and actual administration often has greater value than immediate repeat invasive investigation. If euthyroidism is stable and the effusion recurs, exclusive attribution to the thyroid becomes less plausible and should be reassessed. Previous history guides reasoning but should not prevent recognition of a new pericardial disease.

Continuity of treatment is essential after thyroidectomy or radioiodine and in other permanent conditions. The patient should know the dose, method of administration, interactions and need for follow-up even after symptoms disappear. A written plan reduces errors when other prescribers become involved or the formulation changes. If practical or cognitive difficulties exist, organization of administration and follow-up is part of prevention, not an accessory to drug selection.

Return to activities follows clinical stabilization and correction of associated limitations. Restrictions for inflammatory pericarditis do not need to be applied automatically to every non-inflammatory endocrine collection, but a major effusion or cardiac dysfunction requires caution. Increasing dyspnea, presyncope, syncope or renewed general deterioration should bring follow-up forward. Completion of the pericardial pathway does not coincide with stopping endocrine surveillance, which remains necessary to maintain the result over time.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
3. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
4. Chahine J, Ala CK, Gentry JL, Pantalone KM, Klein AL. Pericardial diseases in patients with hypothyroidism. Heart. 2019;105(13):1027-1033.
5. Baldwin C et al. Myxedema Heart and Pseudotamponade. Journal of the Endocrine Society. 2021;5(1):bvaa125.
6. Jonklaas J et al. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751.
7. National Institute for Health and Care Excellence. Thyroid disease: assessment and management. NICE guideline NG145. NICE. 2019. https://www.nice.org.uk/guidance/ng145/chapter/Recommendations (accessed September 26, 2026).
8. Persani L et al. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. European Thyroid Journal. 2018;7(5):225-237.
9. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
10. Ben-Horin S et al. The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. American Journal of Medicine. 2005;118(6):636-640.
11. Saab J et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens. Cancer Cytopathology. 2017;125(2):128-137.
12. Sarode K et al. Pericardial Decompression Syndrome: A Comprehensive Review of a Controversial Entity. International Journal of Angiology. 2024;33(3):139-147.
13. Roberts WC. Pericardial heart disease: its morphologic features and its causes. Proceedings (Baylor University Medical Center). 2005;18(1):38-55.